EANS-Total Voting Rights: Intercell AG / Release according to article 93 BörseG with the aim of a Europe-wide distribution

--------------------------------------------------------------------------------
Total number of voting rights announcement transmitted by euro adhoc. The
issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Intercell AG hereby announces that at the end of the month June 2012 the number
of voting rights amounts to a total of 55.183.961 voting rights.
The change of total voting rights is effective as of 01.06.2012.

additional (optional) statements:
Intercell closes previously announced capital increase
Announcement of the total number of voting rights according to section 93
subsection 1 of the Austrian Stock Exchange Act

Vienna (Austria), June 1, 2012 – Intercell AG (VSE: ICLL) today gave notice of
the completion of the capital increase of 6,591,742 shares which was previously
announced on May 14, 2012. The shares had been placed in an equity private
placement transaction at an issue price of EUR 2.30 per share. Following
registration in the Commercial Register, the new shares have now been issued and
will start trading on the Vienna Stock Exchange today.

According to section 93 subsection 1 of the Austrian Stock Exchange Act, the
management board makes the following announcement: The total number of shares of
common stock with no par value of Intercell AG, each representing one vote, has
increased to 55,183,961. The share capital is now EUR 55,183,961.

The proceeds of the private placement were approximately EUR 15.2 million. The
new shares represent 11.9 percent of Intercell’s total share capital following
the completion of the capital increase.

The equity private placement was part of a combined debt and equity financing of
approximately EUR 35.2 million, consisting of a EUR 20.0 million loan provided
by BB Biotech and the equity private placement of approximately EUR 15.2
million, in which BB Biotech participated in respect of EUR 5.0 million.
Intercell’s biggest shareholder Novartis participated in the equity private
placement pro rata by maintaining its 14.9 percent stake in the Company. Both
the equity and the debt component have now closed.

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | EAE

print